Article

Site-active steroid provides symptomatic relief for patients with dry eye disease

Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
SAHARA trial demonstrates sustained TearCare benefits for evaporative DED
August 8th 2025

SAHARA trial demonstrates sustained TearCare benefits for evaporative DED

3 Things You Should Know About the GA Pipeline
August 8th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan
August 8th 2025

Viridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 8th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: PER-001 showed improved structure and visual function in patients with diabetic retinopathy
August 8th 2025

Q&A: PER-001 showed improved structure and visual function in patients with diabetic retinopathy

Kowa initiates phase 3 safety trial of NCX 470 in Japan
August 8th 2025

Kowa initiates phase 3 safety trial of NCX 470 in Japan

© 2025 MJH Life Sciences

All rights reserved.